{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:21:40Z","timestamp":1792002100798,"version":"4.4.0"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.maturitas.2021.02.007","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T10:20:31Z","timestamp":1614594031000},"page":"19-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations"],"prefix":"10.1016","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9232-4042","authenticated-orcid":false,"given":"Stergios A.","family":"Polyzos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios D.","family":"Anastasilakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7345-7912","authenticated-orcid":false,"given":"Zoe A.","family":"Efstathiadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria P.","family":"Yavropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-3357","authenticated-orcid":false,"given":"Polyzois","family":"Makras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2021.02.007_bib0005","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/EJE-18-0056","article-title":"Therapy of endocrine disease: denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis","volume":"179","author":"Anastasilakis","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0010","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","article-title":"Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"8","author":"Hernlund","year":"2013","journal-title":"Arch. Osteoporos."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0015","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.molmed.2013.05.006","article-title":"Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver","volume":"19","author":"Musso","year":"2013","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0020","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s42000-018-0018-4","article-title":"Obesity and bone metabolism","volume":"17","author":"Savvidis","year":"2018","journal-title":"Hormones (Athens)"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0025","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s13539-014-0146-x","article-title":"Osteosarcopenic obesity: the role of bone, muscle, and fat on health","volume":"5","author":"Ormsbee","year":"2014","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0030","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00198-011-1768-x","article-title":"The effects of adiponectin and leptin on changes in bone mineral density","volume":"23","author":"Barbour","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0035","doi-asserted-by":"crossref","first-page":"E11238","DOI":"10.1073\/pnas.1707876115","article-title":"Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes","volume":"114","author":"Kim","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0040","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/jbmr.2051","article-title":"Relationship of weight, height, and body mass index with fracture risk at different sites in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW)","volume":"29","author":"Compston","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.13733","article-title":"Effect of Weight Loss via Severe vs Moderate Energy Restriction on Lean Mass and Body Composition Among Postmenopausal Women With Obesity: The TEMPO Diet Randomized Clinical Trial","volume":"2","author":"Seimon","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0050","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00198-016-3735-z","article-title":"Three doses of vitamin D, bone mineral density, and geometry in older women during modest weight control in a 1-year randomized controlled trial","volume":"28","author":"Pop","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0055","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1359\/JBMR.041132","article-title":"Overweight postmenopausal women lose bone with moderate weight reduction and 1 g\/day calcium intake","volume":"20","author":"Riedt","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0060","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000500779","article-title":"Is Weight Loss Harmful for Skeletal Health in Obese Older Adults?","volume":"66","author":"Papageorgiou","year":"2020","journal-title":"Gerontology"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0065","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1007\/s11695-009-9890-y","article-title":"Increase of bone resorption and the parathyroid hormone in postmenopausal women in the long-term after Roux-en-Y gastric bypass","volume":"19","author":"Valderas","year":"2009","journal-title":"Obes. Surg."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0070","doi-asserted-by":"crossref","first-page":"e2087","DOI":"10.1097\/MD.0000000000002087","article-title":"Fracture risk after bariatric surgery: a 12-Year nationwide cohort study","volume":"94","author":"Lu","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0075","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1210\/jc.2014-3481","article-title":"Bisphosphonates and glucose homeostasis: a population-based, retrospective cohort study","volume":"100","author":"Toulis","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0080","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.joms.2007.11.032","article-title":"Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study","volume":"66","author":"Wessel","year":"2008","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0085","doi-asserted-by":"crossref","DOI":"10.1007\/s00774-020-01184-0","article-title":"Teriparatide and exercise improve bone, skeletal muscle, and fat parameters in ovariectomized and tail-suspended rats","author":"Sato","year":"2021","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0090","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s00223-016-0226-3","article-title":"Pathophysiology of bone fragility in patients with diabetes","volume":"100","author":"Palermo","year":"2017","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0095","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1210\/jc.2006-0614","article-title":"Risk of fracture in women with type 2 diabetes: the Women\u2019s Health Initiative Observational Study","volume":"91","author":"Bonds","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0100","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1007\/s00198-018-4650-2","article-title":"Diabetes Working Group of, Diagnosis and management of bone fragility in diabetes: an emerging challenge","volume":"29","author":"Ferrari","year":"2018","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0105","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/jbmr.556","article-title":"FRAX underestimates fracture risk in patients with diabetes","volume":"27","author":"Giangregorio","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0110","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s00125-014-3289-6","article-title":"Fracture risk in diabetic elderly men: the MrOS study","volume":"57","author":"Napoli","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0115","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1007\/s00125-005-1786-3","article-title":"Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk","volume":"48","author":"Vestergaard","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0120","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12020-014-0361-4","article-title":"Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists\u2019 treatment: a meta-analysis of randomized controlled trials","volume":"48","author":"Su","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0125","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.08.010","article-title":"Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials","volume":"68","author":"Zhu","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0130","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.2337\/dc11-1099","article-title":"Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials","volume":"34","author":"Monami","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0135","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1210\/jc.2015-1860","article-title":"Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0140","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2337\/dc07-1736","article-title":"Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study","volume":"31","author":"Monami","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0145","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1210\/jc.2015-3167","article-title":"Effects of Canagliflozin on fracture risk in patients with type 2 diabetes mellitus","volume":"101","author":"Watts","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0150","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.maturitas.2013.04.004","article-title":"Diabetes and bone health","volume":"76","author":"Antonopoulou","year":"2013","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0155","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.bone.2010.12.020","article-title":"Serum osteocalcin level is positively associated with insulin sensitivity and secretion in patients with type 2 diabetes","volume":"48","author":"Kanazawa","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0160","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/jbmr.1865","article-title":"Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials","volume":"28","author":"Schwartz","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0165","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1172\/JCI125915","article-title":"RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass","volume":"129","author":"Bonnet","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0170","doi-asserted-by":"crossref","first-page":"e2991","DOI":"10.1002\/dmrr.2991","article-title":"Effect of denosumab on fasting glucose in women with diabetes or prediabetes from the FREEDOM trial","volume":"34","author":"Napoli","year":"2018","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0175","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.fertnstert.2007.03.083","article-title":"Effects of raloxifene on insulin sensitivity, beta-cell function, and hepatic insulin extraction in normal postmenopausal women","volume":"89","author":"Nagamani","year":"2008","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0180","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0149-2918(03)80114-5","article-title":"Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes","volume":"25","author":"Barrett-Connor","year":"2003","journal-title":"Clin. Ther."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0185","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1055\/s-2008-1078729","article-title":"Effect of exogenous intermittent recombinant human PTH 1-34 administration and chronic endogenous parathyroid hormone excess on glucose homeostasis and insulin sensitivity","volume":"40","author":"Anastasilakis","year":"2008","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0190","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1055\/s-2007-967090","article-title":"Acute and chronic effect of teriparatide on glucose metabolism in women with established osteoporosis","volume":"115","author":"Anastasilakis","year":"2007","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0195","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2337\/diacare.27.7.1547","article-title":"t. Fracture intervention, Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial","volume":"27","author":"Keegan","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0200","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00223-010-9450-4","article-title":"Are antiresorptive drugs effective against fractures in patients with diabetes?","volume":"88","author":"Vestergaard","year":"2011","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0205","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s00223-015-0071-9","article-title":"Efficacy and safety of risedronate in osteoporosis subjects with comorbid diabetes, hypertension, and\/or dyslipidemia: a post hoc analysis of phase III trials conducted in Japan","volume":"98","author":"Inoue","year":"2016","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0210","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1359\/jbmr.070904","article-title":"Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial","volume":"23","author":"Ensrud","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0215","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1359\/jbmr.040211","article-title":"Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study","volume":"19","author":"Johnell","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115268","article-title":"Denosumab in postmenopausal women with osteoporosis and diabetes: subgroup analysis of FREEDOM and FREEDOM extension","volume":"134","author":"Ferrari","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0225","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nrendo.2016.153","article-title":"Mechanisms of diabetes mellitus-induced bone fragility","volume":"13","author":"Napoli","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0230","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.bone.2016.06.017","article-title":"Teriparatide in patients with osteoporosis and type 2 diabetes","volume":"91","author":"Schwartz","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0235","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10346","article-title":"Abaloparatide in postmenopausal women with osteoporosis and type 2 diabetes: a post hoc analysis of the ACTIVE study","volume":"4","author":"Dhaliwal","year":"2020","journal-title":"Jbmr Plus"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0240","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay6570","article-title":"Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics","volume":"12","author":"Bovijn","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0245","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jbmr.1803","article-title":"Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus","volume":"28","author":"Hamann","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0250","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0255","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00774-015-0687-x","article-title":"Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease","volume":"34","author":"Polyzos","year":"2016","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0260","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s12020-016-1144-x","article-title":"Circulating periostin in patients with nonalcoholic fatty liver disease","volume":"56","author":"Polyzos","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0265","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00774-016-0807-2","article-title":"Nonalcoholic fatty liver disease and osteoporosis: a systematic review and meta-analysis","volume":"35","author":"Upala","year":"2017","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0270","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/apt.15087","article-title":"Systematic review with meta-analysis: non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density","volume":"49","author":"Mantovani","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0275","article-title":"Increased risk of osteoporosis in patients with nonalcoholic fatty liver disease: a population-based retrospective cohort study","volume":"97","author":"Chen","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0280","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jocd.2019.01.004","article-title":"Bone health in patients with liver diseases","volume":"23","author":"Danford","year":"2020","journal-title":"J. Clin. Densitom."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0285","doi-asserted-by":"crossref","first-page":"546","DOI":"10.2174\/1570161116666180711121949","article-title":"Menopause and non-alcoholic fatty liver disease: a review focusing on therapeutic perspectives","volume":"17","author":"Venetsanaki","year":"2019","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"Suppl 2","key":"10.1016\/j.maturitas.2021.02.007_bib0290","doi-asserted-by":"crossref","first-page":"S975","DOI":"10.1016\/j.dsx.2017.07.025","article-title":"The effects of vitamin D supplementation on metabolic profiles and liver function in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Tabrizi","year":"2017","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0295","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00198-010-1230-5","article-title":"Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget\u2019s disease of bone","volume":"22","author":"Polyzos","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0300","article-title":"Treatment of nonalcoholic fatty liver disease with an anti-osteoporotic medication: a hypothesis on drug repurposing","volume":"146","author":"Polyzos","year":"2020","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0305","article-title":"Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis","volume":"111s","author":"Polyzos","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0310","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.metabol.2016.05.013","article-title":"Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: a systematic review","volume":"65","author":"Polyzos","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0315","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s10654-004-1706-8","article-title":"Atherogenic lipid profile and elevated lipoprotein (a) are associated with lower bone mineral density in early postmenopausal overweight women","volume":"19","author":"Orozco","year":"2004","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0320","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.metabol.2009.11.023","article-title":"Increased bone resorption and impaired bone microarchitecture in short-term and extended high-fat diet-induced obesity","volume":"60","author":"Patsch","year":"2011","journal-title":"Metabolism"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0325","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00223-015-9975-7","article-title":"The effects of atorvastatin on the prevention of osteoporosis and dyslipidemia in the high-fat-fed ovariectomized rats","volume":"96","author":"Lin","year":"2015","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0330","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ultrasmedbio.2008.11.003","article-title":"Analysis of skeletal status by quantitative ultrasonometry in a cohort of postmenopausal women with high blood cholesterol without documented osteoporosis","volume":"35","author":"Nuzzo","year":"2009","journal-title":"Ultrasound Med. Biol."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0335","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s001980170119","article-title":"Unbalanced diet to lower serum cholesterol level is a risk factor for postmenopausal osteoporosis and distal forearm fracture","volume":"12","author":"Varenna","year":"2001","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0340","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1126\/science.286.5446.1946","article-title":"Stimulation of bone formation in vitro and in rodents by statins","volume":"286","author":"Mundy","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0345","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1006\/bbrc.1999.1499","article-title":"Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates","volume":"264","author":"van Beek","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0350","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S8756-3282(03)00034-6","article-title":"Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1-year longitudinal study","volume":"32","author":"Montagnani","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0355","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5387\/fms.57.19","article-title":"Fluvastatin increases bone mineral density in postmenopausal women","volume":"57","author":"Gotoh","year":"2011","journal-title":"Fukushima J. Med. Sci."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0360","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/archinte.164.2.146","article-title":"Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials","volume":"164","author":"Bauer","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0365","first-page":"252","article-title":"Effects of bisphosphonates on lipid metabolism","volume":"29","author":"Guney","year":"2008","journal-title":"Neuro Endocrinol. Lett."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0370","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1359\/jbmr.2000.15.3.599","article-title":"Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol","volume":"15","author":"Adami","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0375","doi-asserted-by":"crossref","first-page":"762","DOI":"10.14740\/jocmr2278w","article-title":"The effects of bazedoxifene on bone, glucose, and lipid metabolism in postmenopausal women with type 2 diabetes: an exploratory pilot study","volume":"7","author":"Yoshii","year":"2015","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0380","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000018067","article-title":"Effect of denosumab, a human monoclonal antibody of receptor activator of nuclear factor kappa-B ligand (RANKL), upon glycemic and metabolic parameters: effect of denosumab on glycemic parameters","volume":"98","author":"Abe","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0385","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1161\/hh2401.101070","article-title":"Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers","volume":"89","author":"Steitz","year":"2001","journal-title":"Circ. Res."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0390","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.yexcr.2016.06.007","article-title":"WNT\/\u03b2-catenin signaling promotes VSMCs to osteogenic transdifferentiation and calcification through directly modulating Runx2 gene expression","volume":"345","author":"Cai","year":"2016","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0395","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.ATV.21.5.817","article-title":"Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption","volume":"21","author":"Price","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0400","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2353\/ajpath.2009.080957","article-title":"Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice","volume":"175","author":"Helas","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0405","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.bone.2008.07.250","article-title":"Differential effects of intermittent PTH(1-34) and PTH(7-34) on bone microarchitecture and aortic calcification in experimental renal failure","volume":"43","author":"Sebastian","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2020.104697","article-title":"Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture","volume":"115","author":"Turk","year":"2020","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0415","doi-asserted-by":"crossref","first-page":"e3069","DOI":"10.1002\/dmrr.3069","article-title":"Sclerostin is expressed in the atherosclerotic plaques of patients who undergoing carotid endarterectomy","volume":"35","author":"Leto","year":"2019","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0420","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/jamainternmed.2019.2779","article-title":"Association between drug treatments for patients with osteoporosis and overall mortality rates: a meta-analysis","volume":"179","author":"Cummings","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0425","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0430","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group","volume":"85","author":"Black","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0435","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2796.2008.02065.x","article-title":"Atrial fibrillation in fracture patients treated with oral bisphosphonates","volume":"265","author":"Abrahamsen","year":"2009","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0440","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/jbmr.2043","article-title":"RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk","volume":"29","author":"Samelson","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0445","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1160\/TH07-07-0468","article-title":"Effect of raloxifene therapy on venous thromboembolism in postmenopausal women","volume":"99","author":"Adomaityte","year":"2008","journal-title":"A meta-analysis, Thromb Haemost"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0450","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00198-010-1302-6","article-title":"Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial","volume":"22","author":"de Villiers","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0455","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of Abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2021.02.007_bib0460","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0465","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0470","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.amjmed.2016.07.013","article-title":"Diuretic use and risk of vertebral fracture in women","volume":"129","author":"Paik","year":"2016","journal-title":"Am. J. Med."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0475","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005185.pub2","article-title":"Thiazide diuretics and the risk of hip fracture","author":"Aung","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.maturitas.2021.02.007_bib0480","first-page":"57","article-title":"ARB users exhibit a lower fracture incidence than ACE inhibitor users among older hypertensive men","volume":"46","author":"Kwok","year":"2017","journal-title":"Age Ageing"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512221000244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512221000244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:17:36Z","timestamp":1759915056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512221000244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":96,"alternative-id":["S0378512221000244"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2021.02.007","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2021.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}